Skip to main content
Publish date:

Kronos Bio Announces Participation In H.C. Wainwright 23rd Annual Global Investment Conference 

SAN MATEO, Calif. and CAMBRIDGE, Mass.

SAN MATEO, Calif. and CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that members of the management team will participate in a fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference on Monday, September 13 th at 7 a.m. ET.

The fireside chat will be webcast live from the  Investors & Media  section of the company's website at  www.kronosbio.com . A replay of the webcast will be archived and available for one month following the event. 

About Kronos Bio, Inc.Kronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing therapies that seek to transform the lives of those affected by cancer. The company focuses on targeting dysregulated transcription factors and the regulatory networks within cells that drive cancerous growth. Kronos Bio's lead investigational therapy is entospletinib, a selective inhibitor targeting spleen tyrosine kinase (SYK) in development for the frontline treatment of NPM1-mutated acute myeloid leukemia (AML). The company is also developing KB-0742, an oral inhibitor of cyclin dependent kinase 9 (CDK9), for the treatment of MYC-amplified solid tumors.

Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass. For more information, visit  www.kronosbio.com or follow the company on  LinkedIn.

Investors: Claudia Styslinger Argot Partners 212-600-1902  kronosbio@argotpartners.com   

Media: Sheryl Seapy Real Chemistry 949-903-4750  sseapy@realchemistry.com